Although a delay of symptomatic disease was observed in AML xenograft models transplanted with either AML cell lines or PDXs carrying shCD84 knockdown, at the time of relapse, AML cells completely bypassed CD84 silencing, further supporting the clonal advantage associated with the expression of high CD84 levels in leukemia cells. This evidence concerns the gene CD84 and acute myeloid leukemia.